Medtronic (MDT) Cash from Financing Activities (2014 - 2026)

Medtronic has disclosed Cash from Financing Activities across 13 years of filings, most recently posting -$2.1 billion for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$2.1 billion, down 19.05% year-over-year; the trailing twelve-month figure through Jan 2026 was -$5.2 billion (up 3.18% YoY), and the FY2025 annual result was -$4.4 billion, up 2.0% from the prior year.
• Cash from Financing Activities came in at -$2.1 billion for Q1 2026 at Medtronic, down from -$395.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $3.0 billion in Q4 2022 to a low of -$4.9 billion in Q2 2023.
• The 5-year median for Cash from Financing Activities is -$1.3 billion (2025), against an average of -$1.2 billion.
• Across the five-year window, Cash from Financing Activities jumped 360.95% in 2022 and tumbled 493.33% in 2024, its largest moves.
• Medtronic's Cash from Financing Activities stood at $3.0 billion in 2022, then sank by 102.99% to -$90.0 million in 2023, then sank by 493.33% to -$534.0 million in 2024, then advanced by 26.03% to -$395.0 million in 2025, then tumbled by 428.35% to -$2.1 billion in 2026.
• The last three Cash from Financing Activities figures came in at -$2.1 billion (Q1 2026), -$395.0 million (Q4 2025), and -$1.4 billion (Q3 2025), per Business Quant data.